FTFrancesco Saverio Tedesco

Francesco Saverio Tedesco

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Francesco Saverio Tedesco has a total of 360 co-authors. Here are the top co-authors by number of shared publications:

  • Giulio Cossu

    Division of Cell Matrix Biology and Regenerative Medicine. University of Manchester

    18 shared publications
  • Sara Benedetti

    Department of Cell and Developmental Biology, University College London, WC1E 6DE London, UK; Molecular and Cellular Immunology Section, Great Ormond Street Institute of Child Health, University College London, WC1N 1EH London, UK; NIHR Great Ormond Street Hospital Biomedical Research Centre, WC1N 1EH London, UK

    14 shared publications
  • Martina Ragazzi

    Department of Cell and Developmental Biology, University College London, WC1E 6DE London, UK

    10 shared publications
  • Mattia Francesco Maria Gerli

    Department of Surgical Biotechnology, Division of Surgery and Interventional Science, University College London, London, UK

    8 shared publications
  • Rossana Tonlorenzi

    Division of Neuroscience, IRCCS Ospedale san Raffaele

    8 shared publications
  • Giulio Cossu

    Division of Cell Matrix Biology & Regenerative Medicine, University of Manchester, M13 9PL, UK

    7 shared publications

Latest Publications

  • Open Access

    Advanced iPSC-based modeling of LMNA-related congenital muscular dystrophy enables development of genetic therapies for muscle laminopathies

    by Daniel Moore, Heather Steele-Stallard, Luca Pinton, Valentina Maria Lionello, Lucia Rossi, Artadokht Aghaeipour, Vanessa Todorow, Salma Jalal, Cherry Tsz Yan Wong, Angela Clara-Hwang, et al.

  • Open Access

    A Single Lipid Nanoparticle Formulation Enables Delivery of Diverse RNA Therapeutics to Human Muscle Models of Duchenne Muscular Dystrophy

    by Paola Galbiati, Delphine Leclerc, Margaux Mombled, Ruqayya Khan, Maelle Ralu, Giorgia Bimbi, Giulia Scalisi, Kamel Mamchaoui, Francesco Saverio Tedesco, Sonia Albini, et al.

    Duchenne muscular dystrophy is a lethal neuromuscular disorder caused by the absence of dystrophin, for which no curative treatment is available. RNA based approaches have shown promising results; however, their evaluation is hindered by the lack of robust and rapid delivery methods for differentiated human muscle cells, which represent the most physiologically relevant in vitro models for assessing therapeutic strategies. Here, we establish a versatile lipid nanoparticle platform enabling efficient delivery of diverse RNA therapeutics across a range of human muscle models, including myotubes, induced pluripotent stem cell-derived myotubes, myoblasts, cardiomyocytes, and 3D engineered skeletal muscle tissues. Remarkably, a single commercially available lipid nanoparticle formulation supports delivery of cargos spanning more than 300-fold in size, from short antisense oligonucleotides (~20 nt) to complex CRISPR-based editors (up to ~6.7 kb), including Cas9 nucleases, adenine base editors, and CRISPRa systems. This enables efficient gene correction and transcriptional modulation, resulting in dystrophin restoration or compensatory utrophin upregulation in relevant Duchenne muscular dystrophy models. Together, our results establish a single lipid nanoparticle formulation as a versatile platform for RNA delivery in human muscle systems and provide a practical framework for the rapid preclinical assessment of emerging therapies for Duchenne muscular dystrophy and other neuromuscular disorders.

  • Open Access

    Genetic Landscape and Diagnostic Outcomes of UK Patients With Congenital Myopathies and Muscular Dystrophies Over a 10-Year Period

    by Gianpaolo Cicala, Jo Mccauley, Rahul Phadke, Juliane Mueller, Stephanie Ann Robb, Adnan Y. Manzur, Pinki Munot, Giovanni Baranello, Mariacristina Scoto, Francesco Saverio Tedesco, et al.

    Congenital myopathies (CMYOs) and congenital muscular dystrophies (CMDs) are rare, clinically and genetically heterogeneous neuromuscular conditions characterized by muscle weakness, usually with onset at birth or in the first few months of life. Next-generation sequencing (NGS) has significantly enhanced diagnostic capabilities and transformed the diagnostic process for such rare conditions. The aim of this study was to describe the outcomes of NGS analysis and genotypic prevalence among patients with CMYO and CMD referred for diagnostic assessment to the National Highly Specialized Service (HSS) at the Dubowitz Neuromuscular Centre in London, United Kingdom, over a period of 10 years. Diagnostic outcomes of all referrals to the HSS for NGS analysis of CMYO and/or CMD gene panels from 2014 to 2023 were included and reviewed. A total of 1,927 patients were referred to the service, and a total of 2,352 genetic analyses were completed over 10 years. Overall, 553 of 1,927 unrelated individuals (28.7%) had a genetic diagnosis of CMYO or CMD, due to pathogenic variant/s in one of 59 genes. A total of 345 patients had a diagnosis of CMYO and 208 had CMD. The most common CMYOs were due to pathogenic variants in RYR1 (23.8%), TTN (10.7%), MTM1 (10.4%), NEB (8.7%), SELENON (7.5%), ACTA1 (6.7%), or DNM2 (4.6%) genes. Pathogenic changes in further 27 CMYO genes were also identified. The most common CMDs were due to pathogenic variants in COL6A1 (20.7%), LAMA2 (15.4%), COL6A2 (13.5%), COL6A3 (7.2%), GMPPB (6.7%), POMGnT1 (6.3%), FKRP (6.3%), or LMNA (4.8%) genes. Pathogenic changes in further 17 CMD genes were also identified. A total of 1,374 patients remained undiagnosed. Of these, 78 patients (5.7%) carried a heterozygous pathogenic change in a recessive gene and 419 patients (30.5%) carried a variant of unknown significance, with variants in RYR1 (17.1%), NEB (14.2%), and TTN (12.7%) genes being the most frequent. This large, real-world cohort provides a comprehensive overview of the genetic distribution of CMYO and CMD in routine practice. Our findings offer a robust framework to guide diagnostic strategies, inform variant interpretation, and support clinical decision making in the genomic era.


  • Open Access

    Advanced human iPSC-based modelling of LMNA -related congenital muscular dystrophy enables development of targeted genetic therapies for muscle laminopathies

    by Daniel P. Moore, Heather B. Steele-Stallard, Luca Pinton, Valentina Maria Lionello, Lucia Rossi, Artadokht Aghaeipour, Salma Jalal, Cherry Tsz Yan Wong, Angela Clara-Hwang, Gisèle Bonne, et al.

    LMNA -related congenital muscular dystrophy (L-CMD) is amongst the most severe forms of laminopathies, which are diseases caused by pathogenic variants in the LMNA gene. LMNA encodes the proteins Lamin A and C, which assemble with Lamin B1 and B2 to form the nuclear lamina: a meshwork providing structural stability to the nucleus that also regulates chromatin organisation and gene expression. Research into L-CMD mechanisms and therapies is hindered by lack of humanised, tissue-specific models that accurately recapitulate disease phenotypes. We previously reported that LMNA -mutant induced pluripotent stem cell (iPSC)-derived skeletal muscle cells have nuclear shape abnormalities and Lamin A/C protein mislocalisation. Here, we expand the selection of L-CMD patient- derived iPSCs and validate disease-associated readouts using a transgene-free based protocol which more accurately mimics skeletal myogenesis. Results showed no overt defects in developmental myogenesis, but recapitulation of pathological nuclear shape abnormalities in 2D and 3D cultures, nuclear envelope protein mislocalisation and transcriptomic alterations across multiple pathogenic LMNA variants. We then utilised this platform to assess LMNA gene editing strategies. CRISPR-based exon removal generated stable RNA and protein Lamin A/C species, without significant normalisation of nuclear morphological phenotypes or transcriptomic profile. Conversely, precise editing of the same mutation showed complete reversal of disease-associated nuclear morphometrics, alongside normalisation of the pro-inflammatory transcriptomic signature. Our data provide the foundation for a humanised in vitro disease and therapy modelling platform for this complex and severe muscle disorder. GRAPHICAL HIGHLIGHTS: LMNA -mutant iPSCs undergo efficient skeletal myogenesis upon transgene-free, small molecule-based lineage-directed differentiation L-CMD iPSCs recapitulate hallmark disease-associated nuclear phenotypes and show a pro-inflammatory transcriptional profile Disease modelling platforms based on iPSC-derived skeletal muscle cells enable comparative testing of gene editing strategies CRISPR-edited L-CMD iPSC-derived myogenic cells show amelioration of disease-associated readouts


  • Open Access

    VISIBLE: An imaging-driven system for sampling, biofabrication, and manipulation of complex biological models

    by Sudeep Joshi, Carmen Moreno-Gonzalez, Pacharaporn Suklai, Eugenia Carraro, Colin D.H. Ratcliffe, Giulia L.M. Boezio, George Konstantinou, Xavier Cano-Ferrer, Cathleen Hagemann, Thomas Kavanagh, et al.

    Complex in vitro models (CIVMs), including organoids, spheroids, and bioprinted constructs, have emerged as powerful platforms for recapitulating human tissue architecture and function. However, their inherent heterogeneity and dynamic nature pose significant challenges for standardization, reproducibility, and real-time manipulation. Here, we present VISIBLE (Versatile Imaging-Based Interactive Sampling and Bioprinting System), a modular, imaging-guided platform that integrates real-time monitoring with automated manipulation and 3D bioprinting that addresses these challenges. VISIBLE employs a dual-axis system comprising independently controlled tool-heads and microscope stages, enabling precise spatiotemporal interventions within live cultures. We demonstrate the system capabilities across a range of applications, including morphology- and function-based sampling of organoids and neurospheres, interactive 3D bioprinting, serial scratch assays, and real-time cell-cell interaction studies. Furthermore, we illustrate the system utility in translational contexts through the selective sampling and implantation of patient-derived xenograft organoids. VISIBLE supports long-term culture within an integrated incubation environment and accommodates interchangeable tool-heads for scalable, high-throughput workflows. By enabling closed-loop, feedback-controlled experimentation, VISIBLE addresses some of the critical limitations in existing CIVM platforms and offers a new versatile solution for a wide range of biomedical research applications. This work represents a significant step toward the development of autonomous experimental systems for complex tissue modelling and preclinical investigation.


  • Open Access

    Metabolic remodelling in hiPSC-derived myofibres carrying the m.3243A>G mutation

    by Gabriel E. Valdebenito, Anitta R. Chacko, Chih-Yao Chung, Preethi Sheshadri, Haoyu Chi, Benjamin O’callaghan, Henry Houlden, Hannah Rouse, Valle Morales, Katiuscia Bianchi, et al.

    Summary: Mutations in mitochondrial DNA cause severe multisystem disease, frequently associated with muscle weakness. The m.3243A>G mutation is the major cause of Mitochondrial Encephalomyopathy Lactic Acidosis and Stroke Like episodes (MELAS). Experimental models that recapitulate the disease phenotype in vitro for disease modelling or drug screening are very limited. We have therefore generated hiPSC-derived muscle fibres with variable heteroplasmic mtDNA mutation load without significantly affecting muscle differentiation potential. The cells are excitable and show physiological characteristics of muscle fibres and show well organised myofibrillar structure. In cells carrying the m.3243A>G, the mitochondrial membrane potential and oxygen consumption were reduced in relation to the mutant load. We have shown through proteomic, phosphoproteomic, and metabolomic analyses that the m.3243A>G mutation variably affects the cell phenotype in relation to the mutant load. This variation is reflected by an increase in the NADH/NAD + ratio, which in turns influences key nutrient-sensing pathways in the myofibres. This model enables detailed study of the impact of the mutation on cellular bioenergetics and on muscle physiology with the potential to provide a platform for drug screening.

  • Open Access

    CRISPR-Cas9 mediated endogenous utrophin upregulation improves Duchenne Muscular Dystrophy

    by Simon Guiraud, Sumitava Dastidar, Fetta Mazed, Fatima Amor, Maelle Ralu, Anne de Cian, Isabelle Richard, Giuseppe Ronzitti, Francesco Saverio Tedesco, Mario Amendola

    Duchenne muscular dystrophy (DMD) is a lethal neuromuscular disorder caused by loss of dystrophin. Upregulation of utrophin (UTRN), a dystrophin paralogue, is a promising therapeutic avenue. Here, we present a CRISPR-Cas9-mediated strategy to increase utrophin expression by disrupting microRNA (miR) binding sites (BS). Using a Cas9/gRNA ribonucleoprotein (RNP) complex we disrupted several miR BS in DMD myoblasts and selected the Let-7c BS has crucial for UTRN repression. Interestingly, Cas9/gRNA indels were as efficient as the complete removal of Let-7c BS in upregulating UTRN expression, without any major off-targets. In three-dimensional human DMD cultures, Cas9/gRNA-mediated editing resulted in significant utrophin upregulation and functional improvements of calcium dysregulation and muscle contraction. Finally, Let-7c BS disruption in mdx animals by systemic rAAVs mediated delivery of Cas9 and gRNA resulted in utrophin upregulation and amelioration of the muscle histopathological phenotype. These findings provide the foundations for a universal (mutation-independent) gene editing therapeutic strategy for DMD. One Sentence Summary: CRISPR-Cas9 has the potential to upregulate utrophin to treat all DMD patients.

  • Top Cited Papers

    3D human induced pluripotent stem cell–derived bioengineered skeletal muscles for tissue, disease and therapy modeling

    by Luca Pinton, Moustafa Khedr, Valentina M. Lionello, Shilpita Sarcar, Sara M. Maffioletti, Sumitava Dastidar, Elisa Negroni, SungWoo Choi, Noreen Khokhar, Anne Bigot, et al.

    Skeletal muscle is a complex tissue composed of multinucleated myofibers responsible for force generation that are supported by multiple cell types. Many severe and lethal disorders affect skeletal muscle; therefore, engineering models to reproduce such cellular complexity and function are instrumental for investigating muscle pathophysiology and developing therapies. Here, we detail the modular 3D bioengineering of multilineage skeletal muscles from human induced pluripotent stem cells, which are first differentiated into myogenic, neural and vascular progenitor cells and then combined within 3D hydrogels under tension to generate an aligned myofiber scaffold containing vascular networks and motor neurons. 3D bioengineered muscles recapitulate morphological and functional features of human skeletal muscle, including establishment of a pool of cells expressing muscle stem cell markers. Importantly, bioengineered muscles provide a high-fidelity platform to study muscle pathology, such as emergence of dysmorphic nuclei in muscular dystrophies caused by mutant lamins. The protocol is easy to follow for operators with cell culture experience and takes between 9 and 30 d, depending on the number of cell lineages in the construct. We also provide examples of applications of this advanced platform for testing gene and cell therapies in vitro, as well as for in vivo studies, providing proof of principle of its potential as a tool to develop next-generation neuromuscular or musculoskeletal therapies.


  • Open Access

    Assessing and enhancing migration of human myogenic progenitors using directed iPS cell differentiation and advanced tissue modelling

    by SungWoo Choi, Giulia Ferrari, Louise A Moyle, Kirsty Mackinlay, Naira Naouar, Salma Jalal, Sara Benedetti, Christine Wells, Francesco Muntoni, Francesco Saverio Tedesco

    Muscle satellite stem cells (MuSCs) are responsible for skeletal muscle growth and regeneration. Despite their differentiation potential, human MuSCs have limited in vitro expansion and in vivo migration capacity, limiting their use in cell therapies for diseases affecting multiple skeletal muscles. Several protocols have been developed to derive MuSC‐like progenitors from human induced pluripotent stem (iPS) cells (hiPSCs) to establish a source of myogenic cells with controllable proliferation and differentiation. However, current hiPSC myogenic derivatives also suffer from limitations of cell migration, ultimately delaying their clinical translation. Here we use a multi‐disciplinary approach including bioinformatics and tissue engineering to show that DLL4 and PDGF‐BB improve migration of hiPSC‐derived myogenic progenitors. Transcriptomic analyses demonstrate that this property is conserved across species and multiple hiPSC lines, consistent with results from single cell motility profiling. Treated cells showed enhanced trans‐endothelial migration in transwell assays. Finally, increased motility was detected in a novel humanised assay to study cell migration using 3D artificial muscles, harnessing advanced tissue modelling to move hiPSCs closer to future muscle gene and cell therapies.